Case Note & Summary
The Plaintiff sought ad-interim relief against the Defendant's use of the trademark 'XIGAMET', claiming it infringed upon their registered trademark 'ZITA-MET'. The Plaintiff, a company engaged in manufacturing and selling pharmaceutical products, had been using 'ZITA-MET' since 2013 and had acquired significant goodwill. The Defendant filed a trademark application for 'XIGAMET' in February 2020, which the Plaintiff opposed in August 2020. The Plaintiff later discovered that the Defendant was selling products under the impugned mark. The Court examined the arguments regarding the similarity of the trademarks, the nature of the products, and the potential for consumer confusion, particularly given the serious implications of confusion in medicinal products. The Court found that the marks were deceptively similar and granted the ad-interim injunction sought by the Plaintiff, emphasizing the need for heightened scrutiny in cases involving pharmaceuticals. The Court rejected the Defendant's claims regarding the distinctiveness of their mark and the lack of confusion, asserting that the Plaintiff's rights as a registered trademark holder were being infringed. The Court also noted that the ongoing proceedings in the Srinagar Court did not preclude the Plaintiff from seeking relief in this case.
Headnote
A) Trademark Law - Deceptive Similarity - Assessment of Similarity - Trade Marks Act, 1999, Section 142 - The Court held that the Defendant's mark 'XIGAMET' is deceptively similar to the Plaintiff's registered trademark 'ZITA-MET' due to phonetic and structural similarities, particularly in the context of medicinal products where confusion could have serious health implications. The Court emphasized the need for a stricter approach in cases involving medicinal products to prevent potential consumer confusion (Paras 32-36).
Issue of Consideration
Whether the impugned mark of the Defendant is deceptively similar to the trade mark of the Plaintiff.
Final Decision
The Court granted the Plaintiff's request for an ad-interim injunction against the Defendant's use of the trademark 'XIGAMET', finding it deceptively similar to 'ZITA-MET'. The Court emphasized the need for strict scrutiny in cases involving medicinal products due to the potential health risks associated with consumer confusion.
Law Points
- Trademark infringement
- Deceptive similarity
- Ad-interim relief
- Public interest
- Pharmaceutical products
